Seromic™ Profiling Assay
Serametrix is now able to extend the scope of Seromic™ Profiling Assays by offering a range of disease-specific proprietary antigen collections. These assays are now available to researchers seeking biomarkers for patient selection and monitoring, prediction of adverse reactions, early detection, drug repurposing and translational medicine.
Immunogenic antigens as proprietary content
Serametrix has acquired collections of the most relevant antigens across several important diseases. All the antigens in our collections are associated with disease, have demonstrated immunogenicity and have strong potential as biomarkers for drug discovery and development. Panels of the most promising human antigens are available through a variety of proteomic technologies, including multiplex miniaturized ELISA, bead-based assays, "dipstick" and standard ELISA format. Each of these formats has been proven to be an effective tool for measuring serum antibodies. Using patient serum samples in conjunction with proprietary content provides an efficient route to discover differences in the humoral immune responses to disease and drugs in patients. These differences can be exploited in several ways to improve clinical strategies.
Figure 1.Prospective antigen 6-plex distinguishing serum samples from responder and non-responder patients to Drug Y.
Multiplex format allows simultaneous detection of autoantibodies
Using the Seromic™ multiplex formats, between 3 and 300 antigens can be measured in a single assay. Our platforms each include high throughput protocols allowing for the accurate profiling of hundreds of serum samples in weeks, not months. State-of-the-art automation and precise liquid handling capability ensure high reproducibility.
Serum is the most accessible biomarker
The measurement of antibodies in patient sera has several advantages when compared to other more conventional biomarker classes. Firstly, serum is a readily accessible tissue requiring relatively non-invasive sampling. Secondly, antibodies provide an amplified response and their relative abundance enables early warning or detection of small changes. Thirdly, a tissue biopsy is not required, which is both invasive and depending on the tumor accessibility, sometimes contains a mixture of various cell types.
Small amounts of sample are necessary
Since the Seromic™ Profiling Assays are high throughput with well controlled automated liquid handling, it is possible to obtain high quality statistically significant data using only μL volumes of serum samples.
Serametrix will supply raw and refined data and work with customer bioinformaticians to interpret these data to reach useful conclusions. And, crucially, the high throughput capabilities and multiple technological capabilities offered by Serametrix mean that candidate biomarker panels can readily be tested in further studies, overcoming the “biomarker bottleneck” that can otherwise hamper the path to validated and clinically useful biomarkers.
To access Serametrix’s current offering of proprietary content, click here today.
To further enhance the value of profiling studies, custom antigens may be added to the current Seromics offering: customer-defined proteins can be cloned, expressed and assayed alongside Serametrix antigens in the same experiment. Custom antigens can include prospective or existing drug targets, including their polymorphic variants, or simply proteins of interest, candidate biomarkers requiring validation, etc. To discuss a possible research study, call or email us today.
Figure 2 : Customers can supply their own clones or ask Serametrix to source them as additions to the current antigen offering.